CV
BMY icon

Counterweight Ventures’s Bristol-Myers Squibb BMY Stock Holding History

Counterweight Ventures’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,187
Closed -$1.3M – 82
2025
Q4 		$1.3M Buy
24,187
+104
+0.4% +$5K 0.73% 43
2025
Q3 		$1.09M Buy
24,083
+2,949
+14% +$138K 0.64% 44
2025
Q2 		$978K Buy
21,134
+432
+2% +$21.2K 0.64% 43
2025
Q1 		$1.26M Buy
20,702
+499
+2% +$29.1K 0.9% 42
2024
Q4 		$1.14M Sell
20,203
-29
-0.1% -$1.62K 0.81% 42
2024
Q3 		$1.05M Sell
20,232
-5,841
-22% -$274K 0.74% 43
2024
Q2 		$1.08M Buy
26,073
+1,971
+8% +$88.2K 0.82% 38
2024
Q1 		$1.31M Buy
24,102
+9,331
+63% +$475K 1.05% 38
2023
Q4 		$758K Buy
+14,771
New +$775K 0.69% 42

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Counterweight Ventures's BMY Position: Q1 2026 in Review

Counterweight Ventures sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 24,187 shares — an estimated $1.3M sold.

Counterweight Ventures first reported a position in BMY in Q4 2023 and held it in 9 quarters. The position peaked at $1.31M in Q1 2024. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Counterweight Ventures reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Counterweight Ventures sold 24,187 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.3M.
  • Counterweight Ventures first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 9 quarters.
  • Counterweight Ventures's Bristol-Myers Squibb position peaked at $1.31M in Q1 2024.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Counterweight Ventures's 13F filing for Q1 2026, filed 27 Apr 2026.